Celldex falls after two probable anaphylaxis cases in trials

** Shares of Celldex Therapeutics CLDX.O down 12.8% to $33.07, set for its biggest one-day fall in just over a year

** The biotech company says its experimental drug barzolvolimab met main and all key secondary endpoints in two late-stage studies for chronic spontaneous urticaria

** Chronic spontaneous urticaria is a condition that causes recurring itchy hives and swelling

** Analysts pointed to safety concerns and efficacy over probable anaphylaxis cases reported in trials weighing on shares

** CLDX had gained as much as 45% to $55 in premarket trading following trial results

** Co plans to file for U.S. FDA approval in 2027

** Fourteen of 15 brokerages rate the stock "buy" or higher, one "hold"; their median PT is $56 — data compiled by LSEG

** Including session moves, CLDX stock up over 21% YTD